Galderma doubles Nemluvio peak sales projection to $4B-plus after strong atopic dermatitis launch year
5th March 2026 Uncategorised 0Galderma has doubled its peak annual sales estimate for Nemluvio (nemolizumab) to more than $4 billion, following what CEO Flemming Ørnskov described as an “outstanding launch trajectory” for the Dupixent competitor in its first full year on the market.
More: Galderma doubles Nemluvio peak sales projection to B-plus after strong atopic dermatitis launch year
Source: fierce